Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 6/2012

01-06-2012 | Original Paper

MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case–control studies

Authors: Jun Wang, Baocheng Wang, Jingwang Bi, Kainan Li, Jianshi Di

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2012

Login to get access

Abstract

Background

P-glycoprotein, the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of environmental toxins and xenobiotics. Epidemiological studies have evaluated the association between MDR1 C3435T polymorphism and cancer susceptibility. However, published data are still inconclusive.

Methods

To derive a more precise assessment of this relevance, we performed a meta-analysis, up to September 2010, of 5,196 cases with different cancer types and 6,827 controls from 34 published case–control studies. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for MDR1 C3435T polymorphism and cancer were estimated using fixed- and random-effects models when appropriate.

Results

The overall results suggested that the variant was associated with a moderately increased cancer risk in all comparison models tested (OR = 1.26, 95% CI: 1.06–1.50 for TT vs. CC; OR = 1.19, 95% CI: 1.04–1.37 for CT vs. CC; OR = 1.15, 95% CI: 1.01–1.32 for recessive model; OR = 1.21, 95% CI: 1.06–1.38 for domain model, and OR = 1.14, 95% CI: 1.04–1.26 for allele contrast). In the subgroup analysis by cancer types, significant associations were found in breast cancer (OR = 1.66, 95% CI: 1.24–2.21 for TT vs. CC; OR = 1.44, 95% CI: 1.14–1.82 for recessive model; OR = 1.41, 95% CI: 1.10–1.81 for domain model; and OR = 1.31, 95% CI: 1.13–1.52 for allele contrast) and renal cancer (OR = 1.99, 95% CI: 1.37–2.90 for TT vs. CC; OR = 1.74, 95% CI: 1.25–2.42 for domain model; OR = 1.43, 95% CI: 1.09–1.88 for recessive model; and OR = 1.40, 95% CI: 1.17–1.68 for allele contrast). However, no significant associations were found in colorectal cancer, gastric cancer, and acute lymphoblastic leukemia for all genetic models. In the ethnicity subgroup analysis, a significant association with cancer among Caucasians was found under the dominant model, homozygote comparison, CT versus CC comparison, and allele comparison.

Conclusions

In summary, this meta-analysis suggests that the MDR1 C3435T polymorphism is associated with cancer susceptibility, increasing the risk of breast and renal cancer.
Literature
Andersen V, Agerstjerne L, Jensen D, Ostergaard M, Saebo M, Hamfjord J, Kure E, Vogel U (2009a) The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study. BMC Med Genet 10:18PubMedCrossRef
Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U (2009b) Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 9:407PubMedCrossRef
Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH, Kang JH (2006) Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 97:774–779PubMedCrossRef
Breier A, Barancik M, Sulova Z, Uhrik B (2005) P-glycoprotein–implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5:457–468PubMedCrossRef
Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, Au WW, Xu X (2010) Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 213:140–145PubMedCrossRef
Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A (2010) MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10:62–69PubMedCrossRef
Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J (2004) P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 31:758–763PubMedCrossRef
Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860–871PubMed
Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gaborieau V, Gioia-Patricola L, Bellini I, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P (2007) Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 28:1287–1293PubMedCrossRef
George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E (2009) A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 9:161–165PubMedCrossRef
Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J (2006) Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer 107:2850–2857PubMedCrossRef
Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I (2007) Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56–65PubMedCrossRef
Hattori H, Suminoe A, Wada M, Koga Y, Kohno K, Okamura J, Hara T, Matsuzaki A (2007) Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res 31:1633–1640PubMedCrossRef
Henriquez-Hernandez LA, Murias-Rosales A, Hernandez Gonzalez A, Cabrera De Leon A, Diaz-Chico BN, Mori De Santiago M, Fernandez Perez L (2009) Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep 22:1425–1433PubMedCrossRef
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMedCrossRef
Humeny A, Rodel F, Rodel C, Sauer R, Fuzesi L, Becker C, Efferth T (2003) MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 23:2735–2740PubMed
Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72:314–321PubMedCrossRef
Jamroziak K, Balcerczak E, Cebula B, Janus A, Mirowski M, Robak T (2006a) No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 28:707–711PubMedCrossRef
Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kaplon A, Mirowski M, Bates SE, Robak T (2006b) MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 58:720–728PubMed
Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, Salagacka A, Mirowski M, Robak T (2009) Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 33:332–335PubMedCrossRef
Khedri A, Nejat-Shokouhi A, Salek R, Esmaeili H, Mokhtarifar A, Entezari Heravi R, Tatari F, Behravan J, Miladpour B, Omidvar Tehrani S (2010) Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep 38:2939–2943PubMedCrossRef
Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21:126–132PubMedCrossRef
Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, Lambrette P, Costea I, Deslandres C, Grimard G, Law L, Levy E, Amre DK (2009) Associations between ABCB1/MDR1 gene polymorphisms and Crohn’s disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis 15:900–908PubMedCrossRef
Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W, Lubinski J (2005) Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61:389–394PubMedCrossRef
Leal-Ugarte E, Gutierrez-Angulo M, Macias-Gomez NM, Peralta-Leal V, Duran-Gonzalez J, De La Luz Ayala-Madrigal M, Partida-Perez M, Barros-Nunez P, Ruiz-Diaz D, Moreno-Ortiz JM, Peregrina-Sandoval J, Meza-Espinoza JP (2008) MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. Hum Biol 80:449–455PubMedCrossRef
Lee BI, Choi KY, Lee KM, Chung WC, Kim BW, Choi H, Cho SH, Kang HJ, Lee JS, Kim MS, Chae HS, Chun IS (2006) Is C3435T polymorphism of MDR1 related to inflammatory bowel disease or colorectal cancer in Korean? Korean J Gastroenterol 47:22–29PubMed
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
Miller KL, Kelsey KT, Wiencke JK, Moghadassi M, Miike R, Liu M, Wrensch M (2005) The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 25:85–90PubMedCrossRef
Mrozikiewicz PM, Seremak-Mrozikiewicz A, Semczuk A, Landt O, Breborowicz GH, Drews K (2007) The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 17:728–731PubMedCrossRef
Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, Sugimoto Y (2006) A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein. Mol Cancer Ther 5:877–884PubMedCrossRef
Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lonning PE, Borresen-Dale AL, Kristensen VN (2007) ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 17:127–136PubMedCrossRef
Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M (2005) Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68:422–431PubMedCrossRef
Osswald E, Johne A, Laschinski G, Arjomand-Nahad F, Malzahn U, Kirchheiner J, Gerloff T, Meisel C, Mrozikiewicz PM, Chernov J, Roots I, Kopke K (2007) Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 63:9–16PubMedCrossRef
Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L (2010) MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol 27:1066–1072PubMedCrossRef
Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, Toncheva D, Oellerich M, von Ahsen N (2008) No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 134:317–322PubMedCrossRef
Potocnik U, Glavac D, Dean M (2008) Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 183:28–34PubMedCrossRef
Sabahi Z, Salek R, Heravi RE, Mosaffa F, Avanaki ZJ, Behravan J (2010) Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. Indian J Cancer 47:317–321PubMedCrossRef
Semsei AF, Erdelyi DJ, Ungvari I, Kamory E, Csokay B, Andrikovics H, Tordai A, Csagoly E, Falus A, Kovacs GT, Szalai C (2008) Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res 32:1214–1220PubMedCrossRef
Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H (2002) Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847–1854PubMedCrossRef
Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Ishizaki T, Hishida A (2008) MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci 83:301–304PubMedCrossRef
Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H (2007) Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 22:1678–1682PubMedCrossRef
Taheri M, Mahjoubi F, Omranipour R (2010) Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 9:34–40PubMedCrossRef
Tatari F, Salek R, Mosaffa F, Khedri A, Behravan J (2009) Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol 28:259–263PubMedCrossRef
Turgut S, Yaren A, Kursunluoglu R, Turgut G (2007) MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 38:539–544PubMedCrossRef
Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL (2007) MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 16:1172–1177PubMedCrossRef
Uwai Y, Masuda S, Goto M, Motohashi H, Saito H, Okuda M, Nakamura E, Ito N, Ogawa O, Inui K (2004) Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 49:40–45PubMedCrossRef
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef
Yan Q, Wajapeyee N (2010) Exploiting cellular senescence to treat cancer and circumvent drug resistance. Cancer Biol Ther 9:166–175PubMedCrossRef
Yuan H, Li X, Wu J, Li J, Qu X, Xu W, Tang W (2008) Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr Med Chem 15:470–476PubMedCrossRef
Metadata
Title
MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case–control studies
Authors
Jun Wang
Baocheng Wang
Jingwang Bi
Kainan Li
Jianshi Di
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1171-9

Other articles of this Issue 6/2012

Journal of Cancer Research and Clinical Oncology 6/2012 Go to the issue

Original Paper

The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma

Original Paper

The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia

Original Paper

The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study

Original Paper

Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer

Original Paper

Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy

Original Paper

Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits